Melanoma following treatment with alemtuzumab for multiple sclerosis

European Journal of Neurology

Volumn 16, Issue 4, 2009, Pages

  Pace, A A ^a,b   Zajicek, J P ^b  

^a Clinical Neurology Research   (United Kingdom)

^b PENINSULA MEDICAL SCHOOL   (United Kingdom)

Author keywords

Alemtuzumab; Melanoma; Multiple sclerosis

Indexed keywords

ALEMTUZUMAB;

ADULT; ANAMNESIS; CASE REPORT; EXCISION; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; LETTER; MELANOMA; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MELANOMA; MULTIPLE SCLEROSIS; NEVUS, PIGMENTED; SKIN NEOPLASMS;

EID: 62849084585     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2009.02552.x     Document Type: Letter

References (9)

1. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. Journal of Neurology 2006 253 : 98 108.
2. Hirst CL, Pace A, Pickersgill TP, et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. Journal of Neurology 2008 255 : 231 238.
3. Coles AJ, Compston DA, Selmaj KW, et al. for the CAMMS223 Trial Investigators. Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis. The New England Journal of Medicine 2008 359 : 1786 1801.
4. Fiegl M, Falkner A, Hopfinger G, et al. for the Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukaemia. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia. Cancer 2006 107 : 2408 2416.
5. Mullen JT, Vartanian TK, Atkins MB. Melanoma complicating treatment with Natalizumab for multiple sclerosis. The New England Journal of Medicine 2008 358 : 647 8.
6. Gibbs E, Tremlett H, Ball N, Hashimoto S. Malignant melanoma in a multiple sclerosis patient with persistent neutralising antibodies to interferon-beta. European Journal of Neurology 2008 15 : e4 e4.
7. Garofalo A, Chirivi RG, Foglieni C, et al. Involvement of the very late antigen 4 integrin on melanoma in interleukin 1-augmented experimental metastases. Cancer Research 1995 55 : 414 419.
8. Klemke M, Weschenfelder T, Konstandin MH, Samstag Y, et al. High affinity interaction of integrin alpha4beta1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers. Journal of Cellular Physiology 2007 212 : 368 374.
9. Panzara MA, Bozic C, Sandrock AW. More on melanoma with transdifferentiation - authors' reply. The New England Journal of Medicine 2008 359 : 99 100.